Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Holdings

4,675.42
+15.540.33%
Number of Gainers:46
Number of Losers:17
Number of Flat:2
PE:- -
High:4,702.52
Open:4,659.02
Low:4,658.94
Close:4,659.62
Volume:78.73M
Turnover:6.18B
Market Cap:8.36T
Float Cap:7.89T

Loading ...

Alibaba Group Holding Ltd. ADR Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Aug 13

Kura Oncology, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Allogene Therapeutics Q2 Loss Narrows

MT Newswires Live
·
Aug 13

Keurig Dr Pepper Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 13

Airbnb Inc. Cl a Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Aug 13

Uber Technologies Inc. Stock Falls 4.0%, Underperforms Peers

Dow Jones
·
Aug 13

Why Is Taiwan Semiconductor Manufacturing (TSM) Raising Spending After 45% July Growth?

Simply Wall St.
·
Aug 13

Allogene Therapeutics - May Offer up to $500 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Aug 13

Longeveron Q2 Net Loss Widens on Higher Legal, Clinical Trial Costs

Reuters
·
Aug 13

US Stocks Close: Nasdaq Gains 0.54%; Memory Stocks Lead Gains, SK Hynix, SpaceX Rise 9%

TradingKey
·
Aug 13

Oncology Device Maker RenovoRx's Q2 Revenue Surges, Raises FY Outlook

Reuters
·
Aug 13

MaxCyte Q2 Revenue Beats Estimates

Reuters
·
Aug 13

Aligos Says Partner Amoytop Doses First Participant in Phase 1 Trial of HBV Drug ALG-170675 in China

Reuters
·
Aug 13

Kura Oncology Q2 Product Revenue Rises 57% on Komzifti Uptake

Reuters
·
Aug 13

Omeros Q2 Yartemlea Net Revenue Jumps 190%

Reuters
·
Aug 13

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

THOMSON REUTERS
·
Aug 13

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of Its Potentially Best-in-Class Antisense Oligonucleotide Alg-170675 by Its Partner Amoytop in China

THOMSON REUTERS
·
Aug 13

Kura Oncology 2Q FY26 Net Loss Widens to $68.3 Million; Revenue Rises to $20.87 Million

Reuters
·
Aug 13

Kura Oncology Q2 Operating Expenses USD 93.884 Million

Reuters
·
Aug 13

Kura Oncology Q2 Net Income USD -68.327 Million

THOMSON REUTERS
·
Aug 13